Advertisement

CNS Drugs

, Volume 32, Issue 4, pp 399–400 | Cite as

Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

  • Lawrence W. Elmer
  • Jorge L. Juncos
  • Carlos Singer
  • Daniel D. Truong
  • Susan R. Criswell
  • Sotirios Parashos
  • Larissa Felt
  • Reed Johnson
  • Rajiv Patni
Author Correction

1 Author Correction to: CNS Drugs  https://doi.org/10.1007/s40263-018-0498-4

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted:

Table 2, Primary efficacy results for the phase III studies and pooled populations at week 12: in the ‘Pooled’ section of the table, the ‘Placebo’ and ‘ADS-5102’ column headings are transposed. The corrected table is shown in the following page.

The original article has been corrected.
Table 2

Primary efficacy results for the phase III studies and pooled populations at week 12

Parameter

EASE LID

EASE LID 3

Pooled

LS mean change from baseline (SE)

LS mean change from baseline (SE)

LS mean change from baseline (SE)

ADS-5102 [n = 63]

Placebo [n = 58]

Treatment differencea [95% CI]

p valueb

ADS-5102 [n = 37]

Placebo [n = 38]

Treatment differencea [95% CI]

p valueb

ADS-5102 [n = 100]

Placebo [n = 96]

Treatment differencea [95% CI]

p valueb

UDysRS total score, absolute

− 15.9 (1.6)

− 8.0 (1.6)

− 7.9 (− 12.5, − 3.3)

0.0009

− 20.7 (2.2)

− 6.3 (2.1)

− 14.4 (− 20.4, − 8.3)

< 0.0001

− 17.7 (1.3)

− 7.6 (1.3)

− 10.1 (− 13.8, − 6.5)

< 0.0001

UDysRS total score, relative, %

− 37.0 (5.8)

− 11.6 (5.9)

− 25.4 (− 41.7, − 9.0)

0.0027

− 45.8 (5.2)

− 16.3 (4.9)

− 29.6 (− 43.9, − 15.3)

< 0.0001

− 41.1 (4.2)

− 13.9 (4.1)

− 27.3 (− 38.7, − 15.8)

< 0.0001

UDysRS historical score (Parts I and II)

− 9.9 (1.0)

− 5.4 (1.0)

− 4.5 (− 7.4, − 1.6)

0.0027

− 12.1 (1.5)

− 4.0 (1.4)

− 8.1 (− 12.1, − 4.1)

0.0001

− 10.7 (0.86)

− 5.1 (0.84)

− 5.6 (− 8.0, − 3.3)

< 0.0001

UDysRS objective score

(Parts III and IV)

− 6.1 (0.9)

− 2.7 (1.0)

− 3.4 (− 6.1, − 0.8)

0.0120

− 8.7 (1.3)

− 2.2 (1.2)

− 6.5 (− 10.1, − 3.0)

0.0004

− 7.0 (0.76)

− 2.5 (0.75)

− 4.5 (− 6.6, − 2.4)

< 0.0001

CI confidence interval, LS least squares, SE standard error, UDysRS Unified Dyskinesia Rating Scale

aADS-5102–placebo

bP values are based on the comparison of ADS-5102 versus placebo from the mixed effect model repeat measurement model

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Lawrence W. Elmer
    • 1
  • Jorge L. Juncos
    • 2
  • Carlos Singer
    • 3
  • Daniel D. Truong
    • 4
  • Susan R. Criswell
    • 5
  • Sotirios Parashos
    • 6
  • Larissa Felt
    • 7
  • Reed Johnson
    • 7
  • Rajiv Patni
    • 7
  1. 1.Department of NeurologyUniversity of Toledo College of MedicineToledoUSA
  2. 2.Department of Neurology and Movement DisordersEmory University School of MedicineAtlantaUSA
  3. 3.Department of NeurologyUniversity of MiamiMiamiUSA
  4. 4.The Parkinson’s and Movement Disorder InstituteFountain ValleyUSA
  5. 5.Department of NeurologyWashington UniversitySt. LouisUSA
  6. 6.Struthers Parkinson’s CenterGolden ValleyUSA
  7. 7.Adamas Pharmaceuticals, Inc.EmeryvilleUSA

Personalised recommendations